Effects of 24-week treatment with acarbose on glucagon-like peptide 1 in newly diagnosed type 2 diabetic patients: a preliminary report

BACKGROUND: Treatment with the alpha-glucosidase inhibitor (AGI) acarbose is associated with a significant reduction the risk of cardiovascular events. However, the underlying mechanisms of this effect are unclear. AGIs were recently suggested to participate in stimulating glucagon-like peptide 1 (G...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Miao-yan, Yang, Ju-hong, Shan, Chun-yan, Zhou, Hong-tao, Xu, Yan-guang, Wang, Ying, Ren, Hui-zhu, Chang, Bao-cheng, Chen, Li-ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3653752/
https://www.ncbi.nlm.nih.gov/pubmed/23642288
http://dx.doi.org/10.1186/1475-2840-12-73

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3653752/
https://www.ncbi.nlm.nih.gov/pubmed/23642288
http://dx.doi.org/10.1186/1475-2840-12-73

Ejemplares similares